Phage-based prevention as a complementary outbreak tool

Sponsored By:

Minmin Yen

Ph.D., MPH; CEO & Co-Founder, PhagePro, P.B.C.

Phage-based prevention could protect people at highest risk during outbreaks without adding to rising antimicrobial resistance (AMR) pressures.


As drug resistance spreads, treatment options for bacterial outbreaks continue to narrow. Cholera shows how quickly that door closes: a multidrug-resistant strain identified in Yemen has since spread to East Africa.1 Dr Minmin Yen, CEO and Co-Founder of PhagePro, emphasises: “We are seeing cholera become harder to treat just as the global burden of the disease is rising,” she says. “We cannot afford to rely on antibiotics alone; we need to expand our arsenal of tools to prevent infections.”

The cholera ‘exposure window’

Dr Yen considers the first 48 hours after a cholera case is identified to be critical: household contacts face heightened infection risk with few preventative options beyond hygiene advice. 2 “Every course of antibiotics carries a cost in terms of resistance pressure, so we need alternative ways to protect those most at risk,” she explains. “Without effective prevention during this exposure window, a handful of cases can quickly become a global crisis.” After more than a century without a cholera outbreak, Haiti saw the disease spread nationwide within weeks during an outbreak in 2010.

Every course of antibiotics carries a cost in terms of resistance pressure, so we need alternative ways to protect those most at risk

Phage as a targeted, non-antibiotic layer of protection

Bacteriophages, or phages, are viruses considered natural predators of bacteria. PhagePro is developing an oral phage-based intervention designed to target specific strains of Vibrio cholerae, the bacterium responsible for cholera, providing complementary, targeted protection during cholera outbreaks.

“The question is no longer simply which antibiotic we should use once someone is infected,” explains Dr Yen. “Phage-based prevention offers a fast-acting, targeted protection as a complement to vaccines, clean water and treatment, without adding to antibiotic resistance, providing an answer to both AMR and global health equity.3”

PhagePro works with regulators, outbreak-response experts, and development partners to build the evidence and mobilise the funding needed to bring phage-based prevention to those most at risk. “While treatment manages the disease, phage-based prevention reduces the need for antibiotics in the first place, helping to preserve their effectiveness for when they are needed most,” concludes Dr Yen.

[1] Rouard C, et. al. Long-distance spread of a highly drug-resistant epidemic cholera strain. N Engl J Med. 2024;391(23):2271–2273. doi:10.1056/NEJMc2408761. PMID: 39665659.
[2] Weil AA, et. al. Clinical outcomes in household contacts of patients with cholera in Bangladesh. Clin Infect Dis. 2009;49(10):1473–1479. doi:10.1086/644779. PMID: 19842974.
[3] Yen M, et al. A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models. Nat Commun. 2017;8:14187. doi:10.1038/ncomms14187. PMID: 28146150. PMCID: PMC5296635.
[4] Centers for Disease Control and Prevention. Update: cholera outbreak – Haiti, 2010. MMWR Morb Mortal Wkly Rep. 2010;59(45):1473–1479. PMID: 21085088.

More from AMR & Infectious Diseases